
# Title 21 - Food and Drugs
## Chapter I - Food and Drug Administration, Department of Health and Human Services
### Subchapter C - Drugs: General
#### PART 201 - LABELING
##### Subpart C - Labeling Requirements for Over-the-Counter Drugs
###### ยง 201.80 Specific requirements on content and format of labeling for human prescription drug and biological products; older drugs not described in ยง 201.56(b)(1).
####### c,Name of drug,name,s,of species,x,Name of drug,name of drug,name of drug,Name of drug

() If animal reproduction studies have shown an adverse effect on the fetus, if there are no adequate and well-controlled studies in humans, and if the benefits from the use of the drug in pregnant women may be acceptable despite its potential risks, the labeling shall state: " () has been shown to be teratogenic (or to have an embryocidal effect or other adverse effect) in (()) when given in doses () times the human dose. There are no adequate and well-controlled studies in pregnant women. () should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus." The labeling shall contain a description of the animal studies. If there are no animal reproduction studies and no adequate and well-controlled studies in humans, the labeling shall state: "Animal reproduction studies have not been conducted with (). It is also not known whether () can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. () should be given to a pregnant woman only if clearly needed." The labeling shall contain a description of any available data on the effect of the drug on the later growth, development, and functional maturation of the child.
